EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Anti‐angiogenesis in colorectal cancer therapy

Zhenni Yang iD, Xuqian Zhang iD, Xiaozhe Bai, Xiaonan Xi, Wentian Liu, Weilong Zhong iD

Cancer Science · 2024-03 · 115 (3) · 734-751

DOI: 10.1111/cas.16063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 17.01.2024. Verfasst von Zhenni Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Lab…. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 249 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific Research Project of Tianjin Education Commission, National Natural Science Foundation of China, the National Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The morbidity of colorectal cancer (CRC) has risen to third place among malignant tumors worldwide. In addition, CRC is a common cancer in China whose incidence increases annually. Angiogenesis plays an important role in the development of tumors because it can bring the nutrients that cancer cells need and take away metabolic waste. Various mechanisms are involved in the formation of neovascularization, and vascular endothelial growth factor is a key mediator. Meanwhile, angiogenesis inhibitors and drug resistance (DR) are challenges to consider when formulating treatment strategies for patients with different conditions. Thus, this review will discuss the molecules, signaling pathways, microenvironment, treatment, and DR of angiogenesis in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansVascular Endothelial Growth Factor ASignal TransductionAngiogenesis InhibitorsChinaNeovascularization, PathologicTumor Microenvironment

Stichwörter der Autor:innen

VEGFangiogenesiscolorectal cancerdrug resistancetherapy

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China.
  • Department of Gastroenterology and Hepatology, Xing'an League People's Hospital, Xing'an League, China.
  • Department of Gastroenterology and Hepatology, China Aerospace Science and Industry Corporation, Beijing, China.
  • State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.

ORCID-Profile: Zhenni Yang, Xuqian Zhang, Weilong Zhong

Förderung

  • Scientific Research Project of Tianjin Education Commission
  • National Natural Science Foundation of China
  • the National Key Research and Development Program
  • Scientific and Technological Projects of Tianjin
  • Health Science and Technology Project of Tianjin
  • Clinical Medical Research Project of Tianjin Medical University General Hospital
  • Public Hospital Research Joint Fund Technology Project of Inner Mongolia Autonomous Region

Zitieren

APA

Yang, Z., Zhang, X., Bai, X., Xi, X., Liu, W., & Zhong, W. (2024). Anti‐angiogenesis in colorectal cancer therapy. Cancer Science, 115(3), 734-751. https://doi.org/10.1111/cas.16063

Vancouver

Yang Z, Zhang X, Bai X, Xi X, Liu W, Zhong W. Anti‐angiogenesis in colorectal cancer therapy. Cancer Science. 2024;115(3):734-751. doi:10.1111/cas.16063

BibTeX
@article{Yang2024,
  author = {Yang, Zhenni and Zhang, Xuqian and Bai, Xiaozhe and Xi, Xiaonan and Liu, Wentian and Zhong, Weilong},
  title = {Anti‐angiogenesis in colorectal cancer therapy},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {3},
  pages = {734--751},
  doi = {10.1111/cas.16063}
}
Kostenlos starten →